OBJECTIVES: It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and females or different race/ethnic groups. We describe ritonavir-enhanced atazanavir pharmacokinetics in relation to virological failure, safety and tolerability in treatment-naive individuals to investigate potential differences. METHODS: Plasma samples were collected from participants in AIDS Clinical Trials Group Study A5202 for measurement of antiretroviral concentrations. Individual estimates of apparent oral clearance of atazanavir (L/h) were calculated from a one-compartment model and divided into tertiles as slow (<7), middle (7 to <9; reference group) and fast (≥9). Associations between atazanavir clearance and clinical outcomes were estimated with a hazard ratio (HR) from Cox proportional hazards models. Interactions between atazanavir clearance and sex, race/ethnicity and NRTIs were investigated for each of the outcomes. RESULTS: Among 786 participants, average atazanavir clearance was slower in females (n = 131) than males (n = 655). Atazanavir clearance was associated with time to virological failure (P = 0.053) and this relationship differed significantly by sex (P = 0.003). Females in the fast atazanavir clearance group had shorter time to virological failure (HR 3.49; 95% CI 1.24-9.84) compared with the middle (reference) atazanavir clearance group. Among males, the slow atazanavir clearance group had a higher risk of virological failure (HR 2.10; 95% CI 1.16-3.77). CONCLUSIONS:Atazanavir clearance differed by sex. Females with fast clearance and males with slow clearance had increased risk of virological failure.
RCT Entities:
OBJECTIVES: It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and females or different race/ethnic groups. We describe ritonavir-enhanced atazanavir pharmacokinetics in relation to virological failure, safety and tolerability in treatment-naive individuals to investigate potential differences. METHODS: Plasma samples were collected from participants in AIDS Clinical Trials Group Study A5202 for measurement of antiretroviral concentrations. Individual estimates of apparent oral clearance of atazanavir (L/h) were calculated from a one-compartment model and divided into tertiles as slow (<7), middle (7 to <9; reference group) and fast (≥9). Associations between atazanavir clearance and clinical outcomes were estimated with a hazard ratio (HR) from Cox proportional hazards models. Interactions between atazanavir clearance and sex, race/ethnicity and NRTIs were investigated for each of the outcomes. RESULTS: Among 786 participants, average atazanavir clearance was slower in females (n = 131) than males (n = 655). Atazanavir clearance was associated with time to virological failure (P = 0.053) and this relationship differed significantly by sex (P = 0.003). Females in the fast atazanavir clearance group had shorter time to virological failure (HR 3.49; 95% CI 1.24-9.84) compared with the middle (reference) atazanavir clearance group. Among males, the slow atazanavir clearance group had a higher risk of virological failure (HR 2.10; 95% CI 1.16-3.77). CONCLUSIONS:Atazanavir clearance differed by sex. Females with fast clearance and males with slow clearance had increased risk of virological failure.
Authors: Kimberly Y Smith; Camlin Tierney; Katie Mollan; Charles S Venuto; Chakra Budhathoki; Qing Ma; Gene D Morse; Paul Sax; David Katzenstein; Catherine Godfrey; Margaret Fischl; Eric S Daar; Ann C Collier Journal: Clin Infect Dis Date: 2013-11-18 Impact factor: 9.079
Authors: Kim Keil; Jill Hochreitter; Robin DiFrancesco; Barry S Zingman; Richard C Reichman; Margaret A Fischl; Barbara Gripshover; Gene D Morse Journal: Ther Drug Monit Date: 2007-02 Impact factor: 3.681
Authors: Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Edward P Acosta; Donald E Mager; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Jyoti S Mathad; Nikhil Gupte; Ashwin Balagopal; David Asmuth; James Hakim; Breno Santos; Cynthia Riviere; Mina Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Noluthando Mwelase; Jyoti Pawar; Sima Berendes; Nagalingeswaran Kumarasamy; Bruno B Andrade; Thomas B Campbell; Judith S Currier; Susan E Cohn; Amita Gupta Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Kathleen E Squires; Benjamin Young; Lizette Santiago; Robin H Dretler; Sharon L Walmsley; Henry H Zhao; Gary E Pakes; Lisa L Ross; Mark S Shaefer Journal: HIV AIDS (Auckl) Date: 2017-03-03
Authors: Brittany A Shelton; Deirdre Sawinski; Paul A MacLennan; Wonjun Lee; Christina Wyatt; Girish Nadkarni; Huma Fatima; Shikha Mehta; Heidi M Crane; Paige Porrett; Bruce Julian; Richard D Moore; Katerina Christopoulos; Jeffrey M Jacobson; Elmi Muller; Joseph J Eron; Michael Saag; Inga Peter; Jayme E Locke Journal: EClinicalMedicine Date: 2022-09-17